TYPE 1 DIABETES
We are conducting a clinical research study for individuals with Type 1 diabetes. The study will compare the effectiveness and safety of two FDA approved long-acting insulin analogs, Toujeo(U-300) and Tresiba in subjects with type 1 diabetes.
To be eligible to participate, you must be at least 18 years old and have type 1 diabetes which has been treated with the same basal (long acting) insulin (like Lantus) plus the same rapid acting insulin that you take before meals for at least one month prior to your initial visit.
Also, this study the therapeutic effect of Toujeo compared to Tresiba on glucose control will be further assessed and understood using Continuous Glucose Monitoring (CGM) system. Two sets, 20 days each, of CGM will be conducted by the participating subjects. You cannot use your own CGM during the study.
This study will be around 18 weeks (1 or 2 weeks of screening followed by a 4-week run-in period, a 12-week treatment period and a 2 to 4 days follow-up period). This involves a maximum of 8 visits to the study doctor's office.
You may qualify to participate in the study if:
You are at least 18 years old
You are diagnosed with Type 1 Diabetes
You have been treated with the same long acting insulin plus the same rapid acting insulin that you take before meals for at least one month
We will provide to you at no cost:
You will receive comprehensive labs, ECGs, Physical Exam etc. which we can forward to your PCP.
You will be compensated for your time and travel $75.00 for each office visit (once completed).
To find out more call or text us at (801) 657-3206 or submit the form below. By contacting us, you are in no way obligated to participate. All information submitted is kept strictly confidential and is never shared or sold to third parties.
***If you are currently on an Insulin Pump, you will not be able to participate in this trial.
What to expect when visiting Kalo Clinical Research as we begin to resume in-person patient visits. At this time, you can schedule a screening appointment for one of our clinical research trials...continue reading